The DPYD gene encodes an enzyme known as dihydropyrimidine dehydrogenase (DPYD), which is critical to the metabolism of fluoropyrimidine drugs, such as 5-FU and capecitabine. It is also the rate-limiting step in the breakdown of pyrimidines, such as uracil and thymine. Mutations in DPYD are known to cause severe 5-FU toxicity as a result of decreased DPYD activity.
Indications for Testing
Patients who are candidates for 5-FU or capecitabine therapy should receive DPYD genotyping prior to starting the treatment regimen, especially if the patients have a personal or family history of 5-FU toxicity.
Private insurance coverage varies by insurance company. The CPT code for DPYD testing is 81400 (provided as guidance only).
Click here to order testing supplies or call Client Services at 800-837–8362.
- Buccal Swabs: 4 sterile buccal swabs
- Blood: 5-10cc whole blood lavender-top EDTA or yellow-top ACD-A tubes
Turnaround Time: 7 business days, faster turnaround available for clinical trials